You are here: Industry Insights > AZ

News List

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines firstwordpharma
August 02, 2021
A hospital in Taiwan, China has begun a clinical study investigating a mix and match approach with COVID-19 vaccines from AstraZeneca and Moderna, Taiwan, China News reported.
AZ to take $100m hit from ending trial of CV drug Epanova pharmaceutical-technology
January 15, 2020
AstraZeneca (AZ) has announced the termination of its Phase III STRENGTH trial of Epanova (omega-3 carboxylic acids) following a recommendation by an Independent Data Monitory Committee that the drug was unlikely to demonstrate cardiovascular (CV) benefit
AZ, Merck's Lynparza lands FDA nod in pancreatic cancer fiercepharma
January 03, 2020
Earlier this month, FDA experts voted—barely—that the agency should approve AstraZeneca and Merck’s Lynparza in pancreatic cancer.
AZ, Transgene to collaborate on immunotherapies pharmatimes
May 10, 2019
AZ, Transgene to collaborate on immunotherapies
AZ/Merck & Co’s Lynparza delays spread of pancreatic cancer pharmaphorum
February 27, 2019
AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease.
AZ’s CEO dismisses “fake news” about his imminent departure pharmaphorum
February 15, 2019
AstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced full year results showing sales growth for the first time in a decade.
AZ’s chief medical officer Bohen quits after shake-up pharmaphorum
January 15, 2019
AstraZeneca’s chief medical officer Sean Bohen is to leave the company following its organisational shake-up.
AZ appoints controversial doctor to lead new oncology unit pharmaphorum
January 09, 2019
AstraZeneca has a new and controversial oncology head after the departure of two key leaders led to a management reshuffle....
AZ’s new COPD inhaler Bevespi Aerosphere approved in EU pharmaphorum
December 24, 2018
AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
Innate Pharma gains rights to AZ’s recently approved leukaemia drug pharmaphorum
December 21, 2018
France’s Innate Pharma has gained rights to AstraZeneca’s recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.

Previous page 1 2 3 4 5 Next page